QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
NASDAQ:NMTR

9 Meters Biopharma (NMTR) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
$0.00
$0.02
52-Week Range
N/A
Volume
40 shs
Average Volume
315,915 shs
Market Capitalization
$1.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.70
NMTR stock logo

About 9 Meters Biopharma Stock (NASDAQ:NMTR)

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.

NMTR Stock News Headlines

Altcoin FRENZY Alert…
Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days…
9 Meters Biopharma, Inc. (NMTRQ)
9 Meters Biopharma Inc (NMTRQ)
9 Meters Biopharma (OTC: NMTR.Q)
Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
Why Are 9 Meters Biopharma Shares Nosediving Today?
Temperato resigns as CEO of Raleigh drugmaker
9 Meters Biopharma (NASDAQ: NMTR)
NMTR - 9 Meters Biopharma, Inc.
Why this Raleigh pharma just cut half its workforce
NMTR 9 Meters Biopharma, Inc.
Raleigh pharma raises $5M as phase 3 study begins
See More Headlines
Receive NMTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 9 Meters Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:NMTR
Fax
N/A
Employees
10
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$1.70
High Stock Price Target
$1.70
Low Stock Price Target
$1.70
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-43,770,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.19 per share

Miscellaneous

Free Float
13,992,000
Market Cap
$1.04 million
Optionable
No Data
Beta
1.36
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Ms. Bethany Sensenig C.M.A. (Age 47)
    M.B.A., Interim CEO & CFO
    Comp: $525.59k
  • Dr. Peter H. R. Green M.D.
    Clinical & Scientific Advisor and Consultant
  • Mr. Joseph A. Murray M.D.
    Clinical & Scientific Advisor and Consultant
  • Dr. Ciaran P. Kelly M.D.
    Clinical & Scientific Advisor and Consultant
  • Dr. Elena Verdu M.D.
    Ph.D., Clinical & Scientific Advisor and Consultant
  • Mr. Markku Mäki M.D.
    Ph.D., Clinical & Scientific Advisor and Consultant
  • Dr. William J. Sandborn M.D. (Age 60)
    Ph.D., Clinical & Scientific Advisor and Consultant
  • Dr. Roger Liddle M.D.
    Clinical & Scientific Advisor and Consultant
  • Dr. Anthony J. Dimarino Jr.
    Clinical & Scientific Advisor and Consultant
  • Dr. Brian Gordon Feagan FRCPC
    M.D., M.P.H., Clinical & Scientific Advisor and Consultant

NMTR Stock Analysis - Frequently Asked Questions

Should I buy or sell 9 Meters Biopharma stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 9 Meters Biopharma in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" NMTR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NMTR, but not buy additional shares or sell existing shares.
View NMTR analyst ratings
or view top-rated stocks.

What is 9 Meters Biopharma's stock price target for 2024?

1 brokers have issued 12-month price objectives for 9 Meters Biopharma's stock. Their NMTR share price targets range from $1.70 to $1.70. On average, they anticipate the company's stock price to reach $1.70 in the next twelve months.
View analysts price targets for NMTR
or view top-rated stocks among Wall Street analysts.

How were 9 Meters Biopharma's earnings last quarter?

9 Meters Biopharma, Inc. (NASDAQ:NMTR) posted its quarterly earnings results on Monday, November, 15th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.74) by $0.26.

When did 9 Meters Biopharma's stock split?

9 Meters Biopharma's stock reverse split on Tuesday, October 18th 2022. The 1-20 reverse split was announced on Tuesday, October 18th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of 9 Meters Biopharma own?
How do I buy shares of 9 Meters Biopharma?

Shares of NMTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NMTR) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners